The pharmaceutical industry is seeing a shift toward personalized medicines, and it’s evolving to deliver this via some exciting new tools.

A prime example is the recent announcement of ATMPS’ Hataali blockchain platform being successfully tested with the University Hospitals Birmingham NHS Foundation Trust’s system interface; denoting it as the world’s first blockchain solution for Advanced Therapeutic Medicinal Products (ATMP).

Taking the digital shift in a different direction, within the life sciences industry TraceLink has now managed to leverage cloud technologies to create the world’s largest network of pharmaceutical supply chain partners and allow them to connect seamlessly.

Add the fact that scientists from Rice University Bioengineering have used deep-learning methods to develop their Metabolite Translator, a computer system that can predict what the in-vivo metabolites of a drug could be in order to identify its potential toxicity, and it’s clear to see that times are changing!

In an industry that is notoriously non-digital, these bold developments are inevitably the foundation blocks of a new and exciting chapter in our history.

Follow us on LinkedIn to stay abreast of all the latest news and events.

Additional News

  • 11 September 2025

    Meet us at CPHI 2025

    This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Quinta-Analytica as a member of Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.

  • 8 September 2025

    Quinta-Analytica successfully passed two onsite FDA inspections

    In the first half of 2025, Quinta-Analytica underwent two onsite inspections by the U.S. Food and Drug Administration (FDA).

  • 21 July 2025

    Boosting Bioanalytical Power for our clients

    New ICP-MS Expands Our Capabilities